Melittin: A Key Ingredient of Bee Venom with Potential Anticancer Activity

Abstract

Cancer remains one of the leading causes of morbidity and mortality worldwide, necessitating the continuous exploration of novel and effective therapeutic strategies. Natural bioactive compounds, particularly animal venom–derived peptides, have gained significant attention due to their diverse pharmacological properties. Melittin, a 26-amino-acid amphipathic peptide and the principal component of honey bee (Apis mellifera) venom, constitutes nearly 40–60% of the venom’s dry weight and exhibits potent anticancer and anti-inflammatory activities. This review provides a comprehensive overview of the origin, biosynthesis, chemical composition, and therapeutic potential of melittin, with a special emphasis on its role in cancer therapy. The multifaceted mechanisms underlying its anticancer action—including membrane disruption, induction of apoptosis, inhibition of angiogenesis, suppression of metastasis, and modulation of key signaling pathways such as PI3K/Akt, JAK/STAT, NF-κB, and VEGF—are critically discussed. Additionally, the anti-inflammatory and immunomodulatory effects of melittin, mediated through downregulation of pro-inflammatory cytokines and oxidative stress pathways, are highlighted. Despite its promising preclinical efficacy, melittin’s nonspecific cytotoxicity and hemolytic activity present major challenges to clinical translation. Recent advances in chemical modification, nanocarrier-based delivery systems, and tumor-targeting conjugation strategies aimed at improving its safety profile and therapeutic index are reviewed. Overall, melittin emerges as a potent bioactive peptide with significant potential in cancer treatment, warranting further investigation to overcome its limitations and enable clinical application.